Sign in
CompletedNo phase

Advanced Technology for Myopia Control in Children and Young Adults

Key facts

Who runs it
University of Faisalabad
Where
Pakistan1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
People taking part
90 people enrolled
Started
1 Jul 2025
Ended
6 Jun 2026
Type of study
Interventional, 3 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Lenslet Spectacles
  • Violet Excitation Filter Glasses
  • Single Vision Lenses
Record updated
25 June 2026

Who can take part

Age
8 years to 20 years
Sex
Women and men
Healthy volunteers
Cannot take part
Show the full registry criteria (14)Hide the full registry criteria

Who can take part

  • Diagnosis of axial myopia (high, moderate, or severe)
  • Age between 8 and 20 years (inclusive)
  • Male or female
  • Willingness to wear prescribed glasses as instructed
  • Willingness to attend all follow-up visits (3, 6, and 9 months)
  • Written informed consent from participant or parent/guardian for minors

Who cannot take part

  • Prior or concurrent myopia treatment other than study interventions
  • Any ocular disease (e.g., cataract, glaucoma, retinal disorders)
  • Any systemic disease affecting vision (e.g., diabetes, Marfan syndrome)
  • History of any ocular surgery
  • Allergic or physical intolerance to glasses materials
  • Any ametropia other than axial myopia (e.g., hyperopia, astigmatism >1.50D)
  • Current contact lens users
  • Non-cooperative patients unwilling to comply with study procedures

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Myopia, or nearsightedness, is increasing rapidly worldwide, especially in children and young adults. This study tested two advanced treatments for slowing myopia progression with one control group: special lenslet spectacles (Stellest with highly aspherical lenslet technology) and violet excitation filter glasses (wavelength 420 nm) and Single vision lenses for controls. The study enrolled 90 participants aged 8 to 20 years from schools and universities in Faisalabad, Pakistan. Participants were randomly assigned to one of three groups: lenslet spectacles, violet filter glasses, or single vision lenses (control group). Visual acuity, contrast sensitivity, Spherical Equivalent and axial length were measured at the start and again after 3, 6, and 9 months and one follow up after cessation of treatment. The study aimed to determine whether these advanced technologies can effectively slow myopia progression compared to standard glasses, providing head-to-head evidence on emerging and established optical interventions for myopia control.

The 3 groups in the trial

  • Lenslet Spectacles (HALT TechnologyTreatment being tested

    Participants receive Essilor Stellest spectacle lenses featuring HALT (Highly Aspheric Lenslet Target) anf violet filter glasses technology. Lenses have 1.6mm thickness, refractive index 1.56, UV 400. Participants are instructed to wear glasses throughout all waking hours for 9 months and for VF atleast 3ours.

    Treatment: Lenslet Spectacles

  • Violet Excitation Filter GlassesTreatment being tested

    Participants receive prescription glasses with violet excitation filter (420 nm wavelength, CR-39 material). Participants are instructed to wear glasses for 3 hours daily (11 AM to 2 PM) for 12 months to align with circadian rhythm.

  • Single Vision LensesExisting treatment, for comparison

    Participants receive standard single vision spectacle lenses (SVS index 1.56). Participants are instructed to wear glasses throughout all waking hours for 12 months.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Role of Advanced Technological Approaches for Myopia Control in Myopic Patients: A Randomized Controlled Trial of Lenslet Spectacles vs. Violet Excitation Filter Glasses vs. Single Vision Lenses
Record updated
25 June 2026